Publications by authors named "Robert C Doebele"

100Publications

HLA class I binding of mutant EGFR peptides in NSCLC is associated with improved survival.

J Thorac Oncol 2020 Sep 11. Epub 2020 Sep 11.

University of Colorado, School of Medicine, Division of Medical Oncology, 12801 E. 17th Avenue, Mail Stop 8117, Research 1 South, Aurora, CO 80045 USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.08.023DOI Listing
September 2020

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.

Cell 2020 Sep 20;182(5):1232-1251.e22. Epub 2020 Aug 20.

Department of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2020.07.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484178PMC
September 2020

Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.

Clin Lung Cancer 2020 Jun 20. Epub 2020 Jun 20.

Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.06.015DOI Listing
June 2020

Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.

BMC Cancer 2020 Mar 4;20(1):177. Epub 2020 Mar 4.

Thoracic Oncology Research Initiative, Division of Medical Oncology, University of Colorado, School of Medicine, 12801 E. 17th Ave., MS 8117, Aurora, CO, 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-6661-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057580PMC
March 2020

Acquired Resistance Is Oncogene and Drug Agnostic.

Authors:
Robert C Doebele

Cancer Cell 2019 10;36(4):347-349

University of Colorado Cancer Center, Aurora, CO, 80045. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.09.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437928PMC
October 2019

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer.

Front Oncol 2019 29;9:195. Epub 2019 Mar 29.

Division of Medical Oncology, Department of Internal Medicine, University of Colorado Cancer Center, Aurora, CO, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00195DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450209PMC
March 2019

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.

Nat Rev Clin Oncol 2019 06;16(6):341-355

Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0173-9DOI Listing
June 2019

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.

J Thorac Oncol 2018 10 20;13(10):1474-1482. Epub 2018 Jun 20.

Department of Medicine - Division of Medical Oncology, University of Colorado - Anschutz Medical Campus, Aurora, Colorado. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.05.041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286810PMC
October 2018

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

N Engl J Med 2018 02;378(8):731-739

From Memorial Sloan Kettering Cancer Center (A. Drilon, J.F.H., R.B., M.L., D.M.H.) and Weill Cornell Medical College (A. Drilon, D.M.H.), New York; University of Texas Southwestern Medical Center-Children's Health, Dallas (T.W.L.); Stanford Cancer Center, Stanford University, Palo Alto (S.K.), Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California (L.M.), and UCLA David Geffen School of Medicine (N.F.), Los Angeles, and Loxo Oncology, South San Francisco (B.B.T., K.E., S.C., N.C.K., M.C.C.) - all in California; Dana-Farber-Boston Children's Cancer and Blood Disorders Center (S.G.D.), Dana-Farber Cancer Institute (G.D.D., M.N.), Ludwig Center at Harvard (G.D.D.), and Massachusetts General Hospital (A.F.F.) - all in Boston; the Finsen Center, Rigshospitalet, Copenhagen (U.N.L.); University of Colorado, Aurora (R.C.D.); St. Jude Children's Research Hospital, Memphis (A.S.P.), and Vanderbilt University, Nashville (J.B.) - both in Tennessee; Cincinnati Children's Hospital Medical Center, Cincinnati (B.T.); University Hospitals of Cleveland Medical Center (A. Dowlati) and Taussig Cancer Institute, Cleveland Clinic (D.P.S.S.), Cleveland; University of Pennsylvania Perelman School of Medicine, Department of Otorhinolaryngology and Head and Neck Surgery, and the Abramson Cancer Center (M.S.B.), and Fox Chase Cancer Center (W.S.E.-D.), Philadelphia; University of Washington-Seattle Cancer Care Alliance (C.B.), Seattle Children's Hospital (E.R.R.), and Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center (D.S. Hawkins), Seattle; University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B., D.S. Hong); Inova Schar Cancer Institute, Falls Church, VA (J.D.); START Madrid, Centro Integral Oncológico Clara Campal, Madrid (V.B.); Nemours Children's Hospital, Orlando (R.N.), and Memorial Cancer Institute-Florida International University, Miami (L.E.R.) - both in Florida; Oregon Health and Science University, Portland (M.T.); and WVU Cancer Institute, West Virginia University, Morgantown (P.C.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857389PMC
February 2018

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.

J Pharmacol Exp Ther 2018 03 20;364(3):494-503. Epub 2017 Dec 20.

Boehringer Ingelheim RCV GmbH Co KG, Vienna, Austria (F.H., U.T.-G., A.B., S.L., D.G., T.V., P.G.-C., C.H., N.K.); University of Colorado, School of Medicine, Division of Medical Oncology, Aurora, Colorado (A.T.L., R.C.D.); and AstraZeneca - Innovative Medicines and Early Development, Discovery Sciences, Cambridge Science Park, Milton, Cambridge (D.G.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.117.244129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040086PMC
March 2018

The importance of the initial response to cancer treatment in predicting longer overall survival.

Expert Rev Clin Pharmacol 2018 02 26;11(2):109-111. Epub 2017 Dec 26.

b Division of Medical Oncology, Department of Medicine , University of Colorado School of Medicine , Aurora , CO , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1419428DOI Listing
February 2018

Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.

J Thorac Oncol 2018 01 24;13(1):134-138. Epub 2017 Aug 24.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.08.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810959PMC
January 2018

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

J Clin Oncol 2017 May 13;35(13):1403-1410. Epub 2017 Mar 13.

Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.9352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559893PMC
May 2017

Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an Gene Fusion.

JCO Precis Oncol 2017 29;2017(1). Epub 2017 Aug 29.

Department of Pathology, University of Colorado - Anschutz Medical Campus, Aurora CO.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844276PMC
http://dx.doi.org/10.1200/PO.17.00117DOI Listing
August 2017

Reply to J.K. Molitoris et al.

J Clin Oncol 2017 03 28;35(7):810-811. Epub 2016 Dec 28.

Chad G. Rusthoven and Robert C. Doebele, University of Colorado School of Medicine, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.9287DOI Listing
March 2017

Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.

Clin Lung Cancer 2016 09 8;17(5):466-469. Epub 2016 Jun 8.

Division of Medical Oncology, Department of Medicine, University of Colorado, Denver, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.05.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378381PMC
September 2016

Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 08 13;34(24):2814-9. Epub 2016 Jun 13.

University of Colorado School of Medicine, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.2410DOI Listing
August 2016

A framework for understanding and targeting residual disease in oncogene-driven solid cancers.

Nat Med 2016 05;22(5):472-8

Department of Medicine and Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384713PMC
May 2016

Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.

Lung Cancer 2016 06 26;96:27-32. Epub 2016 Mar 26.

Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.03.007DOI Listing
June 2016

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.

J Thorac Oncol 2016 08 9;11(8):1273-1281. Epub 2016 Apr 9.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, University of Colorado, Aurora, Colorado. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.04.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961521PMC
August 2016

Rearranging Detection of Gene Rearrangements.

J Thorac Oncol 2015 Aug;10(8):1129-30

*Department of Pathology, and †Department of Medicine, Division of Medical Oncology, University of Colorado - Anschutz Medical Campus, Aurora, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000603DOI Listing
August 2015

Rociletinib in EGFR-mutated non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1700-9

From Massachusetts General Hospital (L.V.S., R.S.H., J.L., Z.P.), Harvard Medical School (L.V.S., G.R.O., R.S.H., Z.P.), and Dana-Farber Cancer Institute (G.R.O.) - all in Boston; the Drug Development Department, Université Paris-Sud, Gustave Roussy Cancer Campus (J.-C.S.), and Institut Gustave Roussy (A.V.), Villejuif - both in France; the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (J.W.G., E.B.G., M.A.M., S.N.), and Stanford Cancer Institute, Stanford University, Stanford (H.A.W., J.W.N.) - both in California; the Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit (S.M.G., C.G., A.J.W.); University of Texas M.D. Anderson Cancer Center, Houston (V.P.); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); the Medical University of Gdansk, Gdansk, Poland (R.D.); the University of Colorado (D.L.A., D.R.C.) and University of Colorado Cancer Center (R.C.D.) - both in Aurora; and Clovis Oncology, San Francisco (M.R., C.A.K., S.J.-T., S.L.M., A.R.A.), Boulder, CO (J.I., D.D.), and Cambridge, United Kingdom (L.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1413654DOI Listing
April 2015

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

J Thorac Oncol 2015 Jan;10(1 Suppl 1):S1-63

*Department of Medical Oncology, Washington University School of Medicine, Saint Louis, Missouri; Departments of †Medical Oncology and ‡Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; §Department of Medical Oncology, University of Colorado School of Medicine and University of Colorado Cancer Center, Aurora, Colorado; ‖UCLA Santa Monica Hematology Oncology, Santa Monica, California; ¶Division of Hematology-Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; #Department of Medical Oncology, Yale School of Medicine and Cancer Center, New Haven, Connecticut; **Massachusetts General Hospital Cancer Center, Boston, Massachusetts; ††Department of Oncology, The University of Chicago Medicine, Chicago, Illinois; ‡‡Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; §§Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia; ‖‖Memorial Sloan-Kettering Cancer Center, New York, New York; ¶¶Division of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina; ##Sarah Cannon Research Institute, Nashville, Tennessee; ***The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; †††Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas; and ‡‡‡Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346098PMC
January 2015

TRKing down an old oncogene in a new era of targeted therapy.

Cancer Discov 2015 Jan 19;5(1):25-34. Epub 2014 Dec 19.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-14-0765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293234PMC
January 2015

Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

J Clin Oncol 2014 Dec 27;32(34):3824-30. Epub 2014 Oct 27.

Puneeth Iyengar, Zabi Wardak, Irma Smith, Chul Ahn, David E. Gerber, Jonathan Dowell, Randall Hughes, Ramzi Abdulrahman, Hak Choy, Robert Timmerman, University of Texas Southwestern Medical Center, Dallas, TX; Brian D. Kavanagh, D. Ross Camidge, Laurie E. Gaspar, Robert C. Doebele, and Paul A. Bunn, University of Colorado School of Medicine, Aurora, CO.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.56.7412
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.7412DOI Listing
December 2014

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Nov 27;371(21):1963-71. Epub 2014 Sep 27.

From the Massachusetts General Hospital Cancer Center (A.T.S., L.P.L., Z.Z., J.W.C., A.J.I.), Dana-Farber Cancer Institute (G.I.S.), and Beth Israel Deaconess Medical Center (D.B.C.) - all in Boston; University of California at Irvine, Irvine (S.-H.I.O.), and Pfizer Oncology, La Jolla (W.T., S.M.S., L.M.T., J.G.C., K.D.W.) - both in California; Seoul National University Hospital, Seoul, South Korea (Y.-J.B.); University of Colorado, Aurora (D.R.C., M.V.-G., R.C.D.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); University of Chicago, Chicago (R.S.); Memorial Sloan Kettering Cancer Center, New York (G.J.R.); Karolinska Institutet, Stockholm (Z.Z.); and Rho, Chapel Hill, NC (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406766DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264527PMC
November 2014

The minority report: targeting the rare oncogenes in NSCLC.

Curr Treat Options Oncol 2014 Dec;15(4):644-57

Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, 12801 E. 17th Avenue, Aurora, CO, 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-014-0310-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216615PMC
December 2014

A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.

J Thorac Oncol 2014 Oct;9(10):1532-9

*University of Colorado Anschutz Medical Campus, Aurora, CO; †New York University School of Medicine, New York, NY; ‡University of California San Francisco, San Francisco, CA; §Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY; ‖Tower Hematology Oncology Medical Group, Beverly Hills, CA; ¶King's College London, Guy's Hospital, London, United Kingdom; #Swedish Cancer Institute, Seattle, WA; **ImClone Systems, a Wholly-owned Subsidiary of Eli Lilly and Company, Bridgewater, NJ; and ††Cedar Sinai Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000273DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165478PMC
October 2014

The democratization of the oncogene.

Cancer Discov 2014 Aug;4(8):870-2

Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0628DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123669PMC
August 2014

EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.

Clin Lung Cancer 2014 Sep 15;15(5):387-9. Epub 2014 May 15.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2014.04.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160348PMC
September 2014

A nice problem to have: when ALK inhibitor therapy works better than expected.

Authors:
Robert C Doebele

J Thorac Oncol 2014 Apr;9(4):433-5

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine and the University of Colorado Cancer Center, Aurora, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000124DOI Listing
April 2014

Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.

Semin Oncol 2014 Feb 12;41(1):110-25. Epub 2013 Dec 12.

Department of Medicine, Division of Medical Oncology, University of Colorado, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.12.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159759PMC
February 2014

The evolution of tumor classification: a role for genomics?

Cancer Cell 2013 Dec;24(6):693-4

Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado, Denver, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2013.11.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928679PMC
December 2013

Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.

J Thorac Oncol 2013 Sep;8(9):e83-4

Departments of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31829ceb8dDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154819PMC
September 2013

Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer?

Authors:
Robert C Doebele

Nat Rev Clin Oncol 2013 Sep 23;10(9):492-3. Epub 2013 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2013.135DOI Listing
September 2013

Molecular pathways: ROS1 fusion proteins in cancer.

Clin Cancer Res 2013 Aug 29;19(15):4040-5. Epub 2013 May 29.

Division of Medical Oncology, Department of Medicine, University of Colorado - Anschutz Medical Campus, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-2851DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732549PMC
August 2013

Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents.

Am Soc Clin Oncol Educ Book 2013

From the Swedish Cancer Institute, Seattle, WA; Dana-Farber Cancer Institute, Boston, MA; University of Colorado Cancer Center, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.e272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142045PMC
November 2015

Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents.

Drugs 2013 May;73(6):517-32

Division of Medical Oncology, Department of Medicine, University of Colorado, Mail Stop 8117, 12801 E. 17th Avenue, Room 8105, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-013-0032-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162404PMC
May 2013

Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.

Cancer 2013 Apr 20;119(8):1467-77. Epub 2012 Dec 20.

Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27913DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935240PMC
April 2013

Targeting ALK, ROS1, and BRAF kinases.

J Thorac Oncol 2012 Dec;7(16 Suppl 5):S375-6

Division of Medical Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31826df05eDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155403PMC
December 2012

A novel interplay between Rap1 and PKA regulates induction of angiogenesis in prostate cancer.

PLoS One 2012 15;7(11):e49893. Epub 2012 Nov 15.

Ben May Department for Cancer Research, The University of Chicago, Chicago, Illinois, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0049893PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499522PMC
April 2013

Oncogenic fusions involving exon 19 of ALK.

J Thorac Oncol 2012 Dec;7(12):e44

Department of Medicine, Division of Medical Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31826bb94dDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963141PMC
December 2012

A time to test, a time to treat.

J Thorac Dis 2012 Apr;4(2):223-5

University of Colorado Cancer Center, Denver, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2072-1439.2012.03.13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378225PMC
April 2012

Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.

Cancer 2012 Nov 4;118(21):5302-9. Epub 2012 Apr 4.

Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.27450
Publisher Site
http://dx.doi.org/10.1002/cncr.27450DOI Listing
November 2012

Treating ALK-positive lung cancer--early successes and future challenges.

Nat Rev Clin Oncol 2012 Apr 3;9(5):268-77. Epub 2012 Apr 3.

Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA. ross.camidge@ ucdenver.edu

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2012.43
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2012.43DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142046PMC
April 2012

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Clin Cancer Res 2012 Mar 10;18(5):1472-82. Epub 2012 Jan 10.

Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80209, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2906DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311875PMC
March 2012

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.

J Thorac Oncol 2011 Apr;6(4):774-80

Department of Medical Oncology, University of Colorado Denver, 1665 North Ursula Street, Room 2256, P.O. Box 6510, Mail Stop F-706, Aurora, CO 80045-0508, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31820cf053DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626562PMC
April 2011

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

Clin Cancer Res 2010 Nov 9;16(22):5581-90. Epub 2010 Nov 9.

Division of Medical Oncology and Department of Pathology, University of Colorado-Denver, 1665 North Ursula Street, Aurora, CO 80045-0508, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0851DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395226PMC
November 2010

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.

Lung Cancer 2010 Jul 25;69(1):1-12. Epub 2010 Jan 25.

University of Colorado Cancer Center, Division of Medical Oncology, Aurora, CO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2009.12.009DOI Listing
July 2010